Prophylactic/therapeutic agent for dry eye

a technology of dry eye and prophylactic acid, which is applied in the direction of antinoxious agents, drug compositions, plant/algae/fungi/lichens ingredients, etc., can solve the problems of excessive viewing of visual display terminals, increased evaporation, and inability to function well of lacrimal liquid, so as to reduce the deterioration of lacrimal secretions and suppress the generation of radical oxygen. , the effect of reducing the deterioration o

Inactive Publication Date: 2015-12-17
ORIZA YUKA KK +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010]On such a background, the inventors of this invention learned that maqui berry extract reduces the deterioration of lacrimal secretion and the generation of radical oxygen in lacrimal gland tissue. They found too that delphinidin glycoside, which is contained much in maqui berry extract, assumes an important role as a physiologically active substance, thus

Problems solved by technology

However, if there are abnormalities in the lacrimal secretion, resulting in changes in the amount or quality of secretion, thus resulting in an increase in the amount of evaporation of the lacrimal liquid or the like, the lacrimal liquid may not function well.
One of the more noticeable causes is the excessive viewing of visual display terminals (VDT).
As computers are being frequently used,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic/therapeutic agent for dry eye
  • Prophylactic/therapeutic agent for dry eye
  • Prophylactic/therapeutic agent for dry eye

Examples

Experimental program
Comparison scheme
Effect test

working example

[0071]Examples of this invention are described herein, which verify the actions, effects or the like of the prophylactic and therapeutic agent for dry eye, of the inhibitor to deterioration of the lacrimal secretory ability, and of the inhibitor to the generation of radical oxygen in the lacrimal gland tissue, which show that the scope of this invention is not limited to its products and manufacturing methods.

working example 1

Preparation of the Maqui Berry Extract

[0072]Maqui berry (Aristotelia Chilensis) fruit in distilled water was stirred at 50 degrees Celsius to obtain the extract liquid. After that, the liquid was filtered and passed through a synthetic-absorbent column chromatography, and then the maqui berry extract liquid containing the active substance was eluted in an aqueous solution of 80% ethanol. Then, the maqui berry extract liquid was dried into the maqui berry extract (Working Example 1). Analyzing the maqui berry extract of Working Example 1 by HPLC, the extract was identified to contain delphinidin 3,5-diglucoside of 12.26% and delphinidin 3-sambubioside-5-glucoside of 7.76%.

working examples 2 to 5

Isolating the Related Ingredients of the Maqui Berry Extract

[0073]In the past, it was identified that the maqui berry extract showed curative action on mice models having dry eye. To find the active substance of the extract, anthocyanin was isolated from the maqui berry and refined.

[0074]As for the method of isolating and refining, the maqui berry extract (0.25 g / 5 ml) obtained by the preparation described in Working Example 1 was filtered through a cotton plug and then passed through an ODS Sep-Pak (Waters Corporation). Then, the extract was isolated and refined by HPLC for sampling. The condition is as follows.

[0075]Mobile phase: 25% MeOH 0.3% TFA

[0076]UV: 520 nm

[0077]Flow rate: 9.0 mL / min

[0078]Column: Inertsil PREP-ODS 20×250 mm

[0079]The following facts were confirmed in isolating and refining the maqui berry extract.

[0080]Delphinidin-3sambubioside-5-glucoside (Fr. 1: Working Example 2) 6.3 mg isolated

[0081]Delphinidin-3,5-diglucoside (Fr. 2: Working Example 3) 6.3 mg isolated

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Description

TECHNICAL FIELD[0001]This invention relates to compositions that allow the eye to increase lacrimal secretion, specifically to increase the amount of lacrim al secretion that has been lessened by functional deterioration due to an excessive use of the eyes.TECHNICAL BACKGROUND[0002]Lacrimal fluid is a thin layer of liquid approximately 7 μm thick that covers the outermost surface of the eyeball. Lacrimal fluid of the outermost surface consists of a three-layer structure of an oil layer, a water layer and a mucin layer. These layers influence one another in adjusting the structure of the lacrimal fluid. Each layer of the lacrimal fluid contains various ingredients such as protein including lactoferrin, lysozyme, IgA (immunoglobulin A), IgG (immunoglobulin G), albumin or the like, wax, cholesterol, glucide, mucin or the like. The function of the lacrimal fluid containing these ingredients is to keep the ocular surface moist to prevent infection from pathogens or the like that enter fr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61K36/185
CPCA61K36/185A61K31/7048A61K31/353A23L33/105A61P27/02A61P27/04A61P39/06
Inventor TSUBOTA, KAZUONAKAMURA, SHIGERUIMADA, TOSHIHIROTANAKA, JUNJIKADEKARU, TAKASHISHIMODA, HIROSHIMURAI, HIROMICHI
Owner ORIZA YUKA KK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap